Suppr超能文献

阿莫西林-克拉维酸治疗自发性细菌性腹膜炎:27例肝硬化患者的前瞻性研究

Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: a prospective study of twenty-seven cases in cirrhotic patients.

作者信息

Grange J D, Amiot X, Grange V, Gutmann L, Biour M, Bodin F, Poupon R

机构信息

Service d'Hépato-gastroentérologie, Hôpital Tenon, Paris, France.

出版信息

Hepatology. 1990 Mar;11(3):360-4. doi: 10.1002/hep.1840110305.

Abstract

Spontaneous bacterial peritonitis in cirrhosis is a serious complication that demands urgent attention. We report here a prospective study of the treatment of 27 episodes of spontaneous bacterial peritonitis in 22 cirrhotic patients with amoxicillin and clavulanic acid. The infection of ascitic fluid was diagnosed by a positive culture plus an ascitic neutrophil count exceeding 75/microliters, or by an ascitic neutrophil count exceeding 500/microliters. The infection was treated with 1 gm amoxicillin and 0.2 gm clavulanic acid every 6 hr for 14 days. In 17 cases (63%), bacteria were isolated from the ascitic fluid. All the bacteria isolated were sensitive to amoxicillin and clavulanic acid, whereas in five cases they were resistant to amoxicillin alone (Escherichia coli in two cases, Klebsiella pneumoniae in two cases and Bacteroides fragilis in one case). Cure of the infection was achieved in 23 episodes (85%) after 14 days' treatment; 17 patients (63%) were able to leave the hospital. Fourteen of 20 patients (70%) treated for the first episode of infection died within 1 yr: eight from infection, two from gastrointestinal hemorrhage, one from infection and hemorrhage and three from tumors. One patient who had repeated infections underwent liver transplantation and has not had any infectious complications 1.5 yr after surgery. Amoxicillin and clavulanic acid may be an effective first-line therapy for ascitic fluid infection in cirrhosis. Nevertheless, the 1-yr prognosis continues to be grave and the severity of the underlying liver disease remains the most important determinant for survival.

摘要

肝硬化患者的自发性细菌性腹膜炎是一种需要紧急关注的严重并发症。我们在此报告一项对22例肝硬化患者的27次自发性细菌性腹膜炎发作采用阿莫西林和克拉维酸进行治疗的前瞻性研究。通过腹水培养阳性加上腹水中性粒细胞计数超过75/微升,或腹水中性粒细胞计数超过500/微升来诊断腹水感染。感染采用每6小时给予1克阿莫西林和0.2克克拉维酸,持续14天进行治疗。17例(63%)患者的腹水培养出细菌。所有分离出的细菌对阿莫西林和克拉维酸敏感,而有5例细菌仅对阿莫西林耐药(2例大肠杆菌、2例肺炎克雷伯菌和1例脆弱拟杆菌)。治疗14天后,23次发作(85%)的感染得到治愈;17例患者(63%)得以出院。20例首次感染接受治疗的患者中有14例(70%)在1年内死亡:8例死于感染,2例死于胃肠道出血,1例死于感染和出血,3例死于肿瘤。1例反复感染的患者接受了肝移植,术后1.5年未出现任何感染并发症。阿莫西林和克拉维酸可能是肝硬化腹水感染的一种有效的一线治疗方法。然而,1年的预后仍然严峻,潜在肝病的严重程度仍然是生存的最重要决定因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验